Trial Profile
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Sepofarsen (Primary)
- Indications Leber congenital amaurosis
- Focus Registrational; Therapeutic Use
- Acronyms ILLUMINATE
- Sponsors ProQR Therapeutics
- 08 Mar 2024 This study has been discontinued in Italy, according to European Clinical Trials Database record.
- 19 Dec 2022 Planned number of patients changed from 33 to 30.
- 08 Dec 2022 This trial has been completed in Germany (Global End Date: 27 Oct 2022) according to European Clinical Trials Database record.